Flare Therapeutics
Cambridge
About Flare Therapeutics
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $205.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2023)
- Website: flaretx.com
- Phone: (857) 706-4400
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/flare-therapeutics-15186 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.